Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- FDA appoints Richard Pazdur as Director of CDER
- Intellia Therapeutics downgraded to Hold from Buy at JonesResearch
- Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Intellia Reports Favorable Phase 1 Data for Nex-Z
- Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial